



		Chopra y & Microbiology) Consultant Pathologist	Dr. Yugam MD CEO & Consultant	(Pathology)
NAME	: Mrs. BABLI ANAND			
AGE/ GENDER	: 63 YRS/FEMALE	Р	ATIENT ID	: 1397763
COLLECTED BY	:	R	EG. NO./LAB NO.	: 012407240009
REFERRED BY	:	R	EGISTRATION DATE	: 24/Jul/2024 08:41 AM
BARCODE NO.	:01513710	C	OLLECTION DATE	: 24/Jul/2024 08:42AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	R	EPORTING DATE	: 24/Jul/2024 10:30AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROA	D, AMBALA CANTT.		
Test Name		Value	Unit	Biological Reference interval
	CL	INICAL CHEMIST	RY/BIOCHEMISTR	Y
			FILE : BASIC	
CHOLESTEROL TOTA by CHOLESTEROL OX		284.01 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.
TRIGLYCERIDES: SER by GLYCEROL PHOSE	UM PHATE OXIDASE (ENZYMATIC)	159.35 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (by SELECTIVE INHIBIT.		54.39	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: 5 by calculated, spe		197.75 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTE by calculated, spe		229.62 ^H	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: by calculated, spe		31.87	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERU by CALCULATED, SPE	M	727.37 ^H	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL by CALCULATED, SPE	RATIO: SERUM	5.22 ^H	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0



an

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

KOS Central Lab:6349/1, Nicholson Road, Ambala Cantt -133 001, HaryanaKOS Molecular Lab:IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt -133 001, Haryana0171-2643898, +91 99910 43898care@koshealthcare.comwww.koshealthcare.comwww.koshealthcare.com







	· · · · · ·	hopra & Microbiology) onsultant Pathologis		(Pathology)
NAME	: Mrs. BABLI ANAND			
AGE/ GENDER	: 63 YRS/FEMALE		PATIENT ID	: 1397763
COLLECTED BY	:		REG. NO./LAB NO.	: 012407240009
REFERRED BY	:		REGISTRATION DATE	: 24/Jul/2024 08:41 AM
BARCODE NO.	:01513710		COLLECTION DATE	: 24/Jul/2024 08:42AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	: 24/Jul/2024 10:30AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD), AMBALA CANTT	ſ	
Test Name		Value	Unit	Biological Reference interval
LDL/HDL RATIO: SEI by CALCULATED, SPI	RUM ECTROPHOTOMETRY	3.64 ^H	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HD		2.93 ^L	RATIO	3.00 - 5.00

INTERPRETATION:

1. Measurements in the same patient can show physiological& analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the

age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







	MD (Pathology & Chairman & Con	Microbiology) sultant Pathologist	MD CEO & Consultant	(Pathology) Pathologist	
NAME	: Mrs. BABLI ANAND				
AGE/ GENDER	: 63 YRS/FEMALE	PATI	ENT ID	: 1397763	
COLLECTED BY	:	REG.	NO./LAB NO.	: 012407240009	
REFERRED BY	:	REGI	STRATION DATE	: 24/Jul/2024 08:41 AM	
BARCODE NO.	:01513710	COLL	ECTION DATE	: 24/Jul/2024 08:42AM	
CLIENT CODE.	: KOS DIAGNOSTIC LAB		RTING DATE	: 24/Jul/2024 10:48AM	
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD,				
CLIENT ADDRESS	. 0349/ I, MICHOLSON ROAD,	AMDALA CAN'I I			
Test Name		Value	Unit	Biological Reference interval	
		V/IT A B / III			
		VITAMII VITAMIN B12/CC			
by CMIA (CHEMILUM IMMUNOASSAY)	ALAMIN: SERUM			190.0 - 890.0	
by CMIA (CHEMILUM IMMUNOASSAY) INTERPRETATION:-		VITAMIN B12/CC > 2000 ^H	BALAMIN		
by CMIA (CHEMILUM IMMUNOASSAY) INTERPRETATION:-	NESCENT MICROPARTICLE SED VITAMIN B12	VITAMIN B12/CC > 2000 ^H	DBALAMIN pg/mL		
IMMUNOASSAY) INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Estro	NESCENT MICROPARTICLE SED VITAMIN B12 nin C gen	VITAMIN B12/CC > 2000 ^H	DBALAMIN pg/mL DECREASED VITAMIN	B12	
by CMIA (CHEMILUM IMMUNOASSAY) INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Estro 3.Ingestion of Vitar	NESCENT MICROPARTICLE SED VITAMIN B12 nin C gen nin A	VITAMIN B12/CC > 2000 ^H 1.Pregnancy 2.DRUGS:Aspir 3.Ethanol Igest	DBALAMIN pg/mL DECREASED VITAMIN in, Anti-convulsants, tion	B12	
by CMIA (CHEMILUM MMUNOASSAY) INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Vitar 3.Ingestion of Vitar 4.Hepatocellular ir	NESCENT MICROPARTICLE SED VITAMIN B12 nin C gen nin A jury	VITAMIN B12/CC > 2000 ^H 1.Pregnancy 2.DRUGS:Aspir 3.Ethanol Igest 4. Contraceptiv	DBALAMIN pg/mL DECREASED VITAMIN in, Anti-convulsants, tion /e Harmones	B12	
by CMIA (CHEMILUM IMMUNOASSAY) INTERPRETATION:- INCREA 1.Ingestion of Vitar 2.Ingestion of Estro 3.Ingestion of Vitar	NESCENT MICROPARTICLE SED VITAMIN B12 nin C gen nin A jury	VITAMIN B12/CC > 2000 ^H 1.Pregnancy 2.DRUGS:Aspir 3.Ethanol Igest	DBALAMIN pg/mL DECREASED VITAMIN in, Anti-convulsants, tion /e Harmones sis	B12	

4.Vitamin B12 deficiency may be due to lack of IF secretion by gastric mucosa (eg, gastrectomy, gastric atrophy) or intestinal malabsorption (eg, ileal resection, small intestinal diseases).

5. Vitamin B12 deficiency frequently causes macrocytic anemia, glossitis, peripheral neuropathy, weakness, hyperreflexia, ataxia, loss of proprioception, poor coordination, and affective behavioral changes. These manifestations may occur in any combination; many patients have the neurologic defects without macrocytic anemia.

6.Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

KOS Diagnostic Lab

(A Unit of KOS Healthcare)

7.Follow-up testing for antibodies to intrinsic factor (IF) is recommended to identify this potential cause of vitamin B12 malabsorption. **NOTE:**A normal serum concentration of vitamin B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for vitamin B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum vitamin B12 concentrations are normal.

*** End Of Report ***





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT